Accessibility Menu
Stella Diagnostics logo

Stella Diagnostics(OTC) SLDX

Market Cap$2.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-99%
1 Year-83%
1 Month-22%
$0.01
+58.82%
+0.00Today
Stella Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-22
Stella Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+58%USD 0.012026-07-15
1 month-21.92%USD 0.012026-06-15
3 month-49.64%USD 0.022026-04-14
Year to date-47.94%USD 0.022025-12-31
1 year-82.6%USD 0.052025-07-22
3 year-92.67%USD 0.112023-07-20
5 year-98.54%USD 0.552021-07-22
Since inception-99.84%USD 5.002008-07-07

Stella Diagnostics Financials at a Glance

Market Cap

$2.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.76M

Net Income (TTM)

-$4.50M

EPS (TTM)

-$0.01

P/E Ratio

-0.58

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$0.01

Volume

20

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.04

Estimated Earnings Date

N/A

SLDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stella Diagnostics

Stella Diagnostics Inc. is a molecular diagnostics company dedicated to improving patient care for individuals with severe esophageal disorders. The firm specializes in clinical tests that provide essential molecular insights, enabling physicians to assess disease progression and potential malignancy.

Products and Services
  • Advanced clinical tests for esophageal disorders
  • Innovative diagnostic tools for enhanced molecular insights
  • Support for healthcare professionals in patient care strategies
Growth Outlook
  • Market demand for molecular diagnostics is increasing significantly
  • Focus on esophageal disorders positions the company uniquely
  • Potential for partnerships with healthcare providers to expand reach
Financial Highlights
  • Recent quarterly revenue of 176,568, showing a focus on growth
  • Trailing twelve months (TTM) revenue of 1,000,000, indicating market interest
  • Operating expenses reflect investment in research and development
Stella Diagnostics Inc. operates in the medical diagnostics and research sector, with a focus on esophageal disorders. The company has made strides in developing specialized clinical tests that provide critical information about the molecular characteristics of patient tissues. This capability allows healthcare providers to make informed decisions regarding disease management. The growth outlook for Stella Diagnostics is promising, driven by an increasing demand for molecular diagnostics and a unique focus on esophageal disorders. The potential for strategic partnerships with healthcare providers could further enhance the company's market presence and service offerings. Financially, the company has reported a recent quarterly revenue of 176,568, which reflects ongoing efforts to establish a foothold in the diagnostics market. The trailing twelve months (TTM) revenue of 1,000,000 indicates a growing interest in the company's offerings. While operating expenses are significant, they are indicative of the company's commitment to research and development, which is essential for long-term growth and innovation in the diagnostics field.
AI Generated • Jul 23, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

3

CEO

David Seaburg

Website

www.stelladx.com

Headquarters

Salt Lake City, UT 84104, US

SLDX Financials

Key Financial Metrics (TTM)

Gross Margin

-34.49%

Operating Margin

-222.71%

Net Income Margin

-255.84%

Return on Equity

17.42%

Return on Capital

N/A

Return on Assets

-3427.32%

Earnings Yield

-1.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

301.50M

Volume

20

Avg. Volume

3.58K

Financials (TTM)

Gross Profit

-$606.77K

Operating Income

-$3.92M

EBITDA

-$3.92M

Operating Cash Flow

-$1.70M

Capital Expenditure

-$4.00

Free Cash Flow

-$1.70M

Cash & ST Invst.

$32.22K

Total Debt

$3.99M

Stella Diagnostics Performance Analysis

Stella Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 1,783,818N/A
Stella Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30185.4%
Q32025-09-30-10.0%
Q42025-12-31-4.9%
Q12026-03-31-64.1%
Stella Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.03-80.2%
20232023-12-31USD -0.02-44.4%
20242024-12-31USD -0.00-83.7%
20252025-12-31USD -0.01277.4%
Stella Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-93.7%
Q32025-09-3035.5%
Q42025-12-31-165.0%
Q12026-03-3132.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$176.57K

-12.3%

Gross Profit

-$10.54K

+91.6%

Gross Margin

-5.97%

N/A

Market Cap

$2.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.21M

N/A

Employees

2

N/A

Net Income

-$1.09M

-68.4%

EBITDA

-$1.03M

-66.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$32.22K

+175.4%

Total Debt

$3.99M

-42.7%

Accounts Receivable

$10.22K

+0.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.99M

-42.3%

Return on Assets

-34.27%

N/A

Return on Invested Capital

14.01%

N/A

Free Cash Flow

-$711.53K

-125.0%

Operating Cash Flow

-$711.53K

-125.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNGGFCann Group Limited
$0.00+0.00%
TBRIFTherma Bright Inc.
$0.04+0.00%
TDSGFTelo Genomics Corp.
$0.03-3.13%
DOGPDogecoin Cash, Inc.
$0.01-14.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About SLDX

What is the current price of Stella Diagnostics?

Stella Diagnostics is trading at $0.01 per share.

What is the 52-week range for Stella Diagnostics?

Over the past 52 weeks, Stella Diagnostics has traded between $0.01 and $0.04.

How much debt does Stella Diagnostics have?

As of the most recent reporting period, Stella Diagnostics reported total debt of $3.99M.

How much cash does Stella Diagnostics have on hand?

Stella Diagnostics reported $32.22K in cash and cash equivalents in its most recent financial results.

What is Stella Diagnostics’s dividend yield?

Stella Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services